🎉 M&A multiples are live!
Check it out!

Roivant Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Roivant Sciences and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Roivant Sciences Overview

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.


Founded

2014

HQ

United States of America
Employees

908

Website

roivant.com

Financials

LTM Revenue $137M

LTM EBITDA -$1.0B

EV

$2.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Roivant Sciences Financials

Roivant Sciences has a last 12-month revenue of $137M and a last 12-month EBITDA of -$1.0B.

In the most recent fiscal year, Roivant Sciences achieved revenue of $125M and an EBITDA of $4.3B.

Roivant Sciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Roivant Sciences valuation multiples based on analyst estimates

Roivant Sciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $61.3M $125M XXX XXX XXX
Gross Profit $46.3M $48.2M XXX XXX XXX
Gross Margin 76% 39% XXX XXX XXX
EBITDA -$1.2B $4.3B XXX XXX XXX
EBITDA Margin -1922% 3454% XXX XXX XXX
Net Profit -$845M -$1.0B XXX XXX XXX
Net Margin -1379% -809% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Roivant Sciences Stock Performance

As of April 15, 2025, Roivant Sciences's stock price is $10.

Roivant Sciences has current market cap of $7.3B, and EV of $2.2B.

See Roivant Sciences trading valuation data

Roivant Sciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.2B $7.3B XXX XXX XXX XXX $-0.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Roivant Sciences Valuation Multiples

As of April 15, 2025, Roivant Sciences has market cap of $7.3B and EV of $2.2B.

Roivant Sciences's trades at 16.3x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.

Analysts estimate Roivant Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Roivant Sciences and 10K+ public comps

Roivant Sciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.2B XXX XXX XXX
EV/Revenue 16.2x XXX XXX XXX
EV/EBITDA 7.1x XXX XXX XXX
P/E 7.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Roivant Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Roivant Sciences Valuation Multiples

Roivant Sciences's NTM/LTM revenue growth is -81%

Roivant Sciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Roivant Sciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Roivant Sciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Roivant Sciences and other 10K+ public comps

Roivant Sciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 104% XXX XXX XXX XXX
EBITDA Margin 229% XXX XXX XXX XXX
EBITDA Growth -466% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 148% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 402% XXX XXX XXX XXX
Opex to Revenue 953% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Roivant Sciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Roivant Sciences M&A and Investment Activity

Roivant Sciences acquired  XXX companies to date.

Last acquisition by Roivant Sciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Roivant Sciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Roivant Sciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Roivant Sciences

When was Roivant Sciences founded? Roivant Sciences was founded in 2014.
Where is Roivant Sciences headquartered? Roivant Sciences is headquartered in United States of America.
How many employees does Roivant Sciences have? As of today, Roivant Sciences has 908 employees.
Who is the CEO of Roivant Sciences? Roivant Sciences's CEO is Mr. Matthew Gline.
Is Roivant Sciences publicy listed? Yes, Roivant Sciences is a public company listed on NAS.
What is the stock symbol of Roivant Sciences? Roivant Sciences trades under ROIV ticker.
When did Roivant Sciences go public? Roivant Sciences went public in 2021.
Who are competitors of Roivant Sciences? Similar companies to Roivant Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Roivant Sciences? Roivant Sciences's current market cap is $7.3B
What is the current revenue of Roivant Sciences? Roivant Sciences's last 12-month revenue is $137M.
What is the current EBITDA of Roivant Sciences? Roivant Sciences's last 12-month EBITDA is -$1.0B.
What is the current EV/Revenue multiple of Roivant Sciences? Current revenue multiple of Roivant Sciences is 16.3x.
What is the current EV/EBITDA multiple of Roivant Sciences? Current EBITDA multiple of Roivant Sciences is -2.2x.
What is the current revenue growth of Roivant Sciences? Roivant Sciences revenue growth between 2023 and 2024 was 104%.
Is Roivant Sciences profitable? Yes, Roivant Sciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.